First-Year Funding of Early Detection Research Network Complete

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 7
Volume 9
Issue 7

BETHESDA, Md-The National Cancer Institute-sponsored Early Detection Research Network has issued 13 grants totaling $18 million to complete its first year of funding. Last fall, NCI awarded $8 million to set up the network’s initial operations-18 biomarker development laboratories. The new grants will finance the establishment of the program’s other three components: clinical and epidemiologic centers, biomarker validation laboratories, and a data management and coordinating center.

BETHESDA, Md—The National Cancer Institute-sponsored Early Detection Research Network has issued 13 grants totaling $18 million to complete its first year of funding. Last fall, NCI awarded $8 million to set up the network’s initial operations—18 biomarker development laboratories. The new grants will finance the establishment of the program’s other three components: clinical and epidemiologic centers, biomarker validation laboratories, and a data management and coordinating center.

The aim of the network is to unite dozens of research institutions in efforts to search for and evaluate new ways to test for early cancer and for cancer risk.

“Advances in cancer genetics, protein analysis, and other fields offer potential new biomarkers that one day may reduce the burden of cancer,” said Sudhir Srivastava, PhD, MPH, chief of the cancer biomarkers research group in NCI’s Division of Cancer Prevention. “But before they can move from the lab to the clinic, these biomarkers need to be tested systematically. Pooling resources and expertise is vital to this kind of validation.”

The new grants will finance:

Nine clinical and epidemiologic centers that will provide the network with blood, tissue, and other biological samples, as well as medical information on families with a history of cancer, for use in a large-scale evaluation of cancer biomarkers.

Three biomarker validation laboratories, which will standardize biomarker tests, assure their reproducibility, and ready the best tests for clinical trials.

A data management and coordination center to develop standards for data reporting and research new statistical methods for analyzing biomarkers.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content